274 completed, 65 terminated, 14 withdrawn, 9 active not recruiting. 192 Phase 2, 185 Phase 1, 28 Phase 3, 4 Not applicable, 4 Phase 4.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 192 | Completed 129, Terminated 43, Withdrawn 9, Unknown 6, Active not recruiting 5 |
| Phase 1 | 185 | Completed 143, Terminated 28, Withdrawn 9, Unknown 4, Active not recruiting 1 |
| Phase 3 | 28 | Completed 23, Active not recruiting 3, Terminated 2 |
| Not applicable | 4 | Completed 3, Unknown 1 |
| Phase 4 | 4 | Completed 4 |
| Early Phase 1 | 1 | Completed 1 |
Follow Millennium Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat
Pevonedistat, Azacitidine - Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes | Phase 2 | Completed | University of Leipzig | 14 | 2021-01-01 | 2023-08-21 |
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
Alzheimer Disease, Progressive Supranuclear Palsy | | Unknown | Xuanwu Hospital, Beijing | 155 | 2020-11-18 | 2022-03-02 |
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Ixazomib - Precursor Cell Lymphoblastic Leukemia-lymphoma | Phase 1 | Withdrawn | Millennium Pharmaceuticals, Inc. | | 2020-10-31 | 2020-09-28 |
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
Mobocertinib - Hepatic Impairment, Healthy Volunteers | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 24 | 2020-10-09 | 2023-11-03 |
Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants
TAK-906 Oral Capsule, [14C]-TAK-906 Intravenous Infusion, [14C]-TAK-906 Oral Solution - Healthy Volunteers | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 6 | 2020-07-30 | 2022-03-07 |
A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
Mobocertinib - Renal Impairment, Healthy Volunteers | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 26 | 2020-03-04 | 2024-01-08 |
A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia
TAK-925, TAK-925 Placebo - Idiopathic Hypersomnia | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 28 | 2020-01-26 | 2023-09-26 |
Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Midazolam, TAK-788 - Carcinoma, Non-Small-Cell Lung, Lung Neoplasms | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 26 | 2019-12-23 | 2025-07-28 |
Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)
TAK-925, Placebo - Obstructive Sleep Apnea | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 25 | 2019-11-21 | 2020-04-20 |
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
TAK-906, Rifampin - Healthy Volunteers | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 12 | 2019-10-15 | 2020-12-09 |
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy
Pevonedistat, Azacitidine - Leukemia, Myeloid, Acute | Phase 3 | Active not recruiting | PETHEMA Foundation | 302 | 2019-09-24 | 2026-06-25 |
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Ponatinib - Medullary Thyroid Cancer | Phase 2 | Withdrawn | Antonio Fojo | | 2019-07-26 | 2021-10-13 |
Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)
Soticlestat, Placebo - Complex Regional Pain Syndrome | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 24 | 2019-07-23 | 2026-09-14 |
A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants
TAK-788, Itraconazole, Rifampin - Healthy Volunteers | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 24 | 2019-05-02 | 2020-08-21 |
A Study to Assess the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics (PK) of TAK-931 in Participants With Advanced Solid Tumors
TAK-931 PIC, TAK-931 Tablet, Esomeprazole - Neoplasms, Advanced Solid | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 20 | 2019-03-28 | 2020-12-29 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants
TAK-954, TAK-954 Placebo - Healthy Volunteers | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 6 | 2019-03-08 | 2020-06-24 |
A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
TAK-906, Esomeprazole - Healthy Volunteers | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 12 | 2019-02-27 | 2021-06-15 |
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Vedolizumab Placebo, Vedolizumab - Hematopoietic Stem Cells | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 343 | 2019-02-06 | 2023-06-06 |
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
Ixazomib - Multiple Myeloma | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 37 | 2019-01-24 | 2025-03-21 |
A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants
Mobocertinib - Healthy Volunteers | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 7 | 2019-01-22 | 2024-02-12 |
Showing 20 of 373. Sign in to see all of them.
Conditions studied
Multiple Myeloma (72) · Lymphoma (39) · Lymphoma, Non-Hodgkin (26) · Prostatic Neoplasms (24) · Leukemia, Myeloid, Acute (21) · Recurrence (18) · Hodgkin Disease (17) · Lymphoma, Mantle-Cell (15) · Carcinoma, Non-Small-Cell Lung (14) · Lymphoma, Follicular (14) · Neoplasms (14) · Myelodysplastic Syndromes (13) · Hematologic Diseases (12) · Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Large-Cell, Anaplastic (11)
Interventions
Bortezomib (147) · Dexamethasone (43) · ixazomib (40) · MLN 8237 (36) · Rituximab (36) · Cyclophosphamide (27) · Brentuximab Vedotin (22) · Lenalidomide (21) · Prednisone (18) · Doxorubicin (17) · pevonedistat (15) · Paclitaxel (14) · orteronel (14) · sapanisertib (14) · Vincristine (13)
Countries
United States (311) · Spain (38) · Canada (35) · United Kingdom (35) · France (29) · Belgium (28) · Italy (27) · Germany (23) · Poland (16) · Netherlands (15) · Australia (14) · Czechia (14) · Israel (13) · Hungary (10) · South Korea (10)
Top investigators
Irene Ghobrial, MD (4) · Maurizio Zangari, MD (4) · Paul Richardson, MD (3) · E. Steve Woodle, MD (2) · Hani Hassoun, MD (2) · John D. Hainsworth, MD (2) · John P Leonard, MD (2) · Melissa Alsina, M.D. (2) · Melissa Alsina, MD (2) · Michael Pishvaian, MD PhD (2) · Naomi Hunder, MD (2)
Results publications
PMID 31355467, PMID 26893500, PMID 25996351, PMID 22510871, PMID 28803351, PMID 29857145, PMID 30203005, PMID 17242396, PMID 21791470, PMID 25135998, PMID 26031410, PMID 28550039, PMID 29272162, PMID 29348128, PMID 30615117, PMID 32635680, PMID 33200296, PMID 15613697, PMID 17553208, PMID 18543319, PMID 18753647, PMID 18829392, PMID 19498019, PMID 19506160, PMID 19528374, PMID 19692142, PMID 19699861, PMID 19713456, PMID 19725827, PMID 20110052, PMID 20142586, PMID 20385792, PMID 20508619, PMID 20628153, PMID 20874823, PMID 21239695, PMID 21345726, PMID 21507715, PMID 21562045, PMID 21724462, PMID 21839411, PMID 22422823, PMID 22454421, PMID 22469559, PMID 22535574, PMID 22614995, PMID 22689675, PMID 22786877, PMID 22899766, PMID 23018640
NIH funding
2008 (7), 2014 (7), 2009 (6), 2018 (5), 2015 (4), 2016 (4), 2017 (4), P30CA060553 (2), P30CA138292 (2), 1KL2TR002346-01 (1), 2019 (1), P30CA014089 (1), P30CA015704 (1), P30CA016672 (1), P30CA093373 (1)